CellCure
London, United Kingdom· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $140M
Overview
Developing stem cell-derived therapies to restore vision in retinal degenerative diseases.
Regenerative MedicineOphthalmology
Technology Platform
A platform for differentiating stem cells into retinal pigment epithelium (RPE) cells for transplantation to treat retinal degeneration.
Funding History
1Total raised:$140M
Public Offering$140M
Opportunities
Addressing the large, untreated patient population with geographic atrophy (dry AMD) where no therapy exists to restore vision.
Risk Factors
Clinical risks include potential immune rejection, incomplete cell integration, and long-term safety concerns associated with stem cell transplants.
Competitive Landscape
Competes directly with other companies developing stem cell-derived RPE transplants for AMD and inherited retinal diseases.